We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Orion Genomics, University of Glasgow Collaborate to Identify Cancer Biomarkers

News   Jan 23, 2006

 
Orion Genomics, University of Glasgow Collaborate to Identify Cancer Biomarkers
 
 
Advertisement
 

RELATED ARTICLES

Insights Into Therapeutic Mechanisms of Cancer Drug Pomalidomide

News

Researchers report novel findings concerning the therapeutic mechanisms of pomalidomide. They showed that pomalidomide causes the breakdown of a protein called ARID2. ARID2 promotes the "expression" of genes that are critical for the growth of multiple myeloma cells, so breaking down ARID2 is harmful to the cancer cells and beneficial to patients.

READ MORE

How the Loss of a Single Protein Leads to a Relentless Neuromuscular Disease

News

A new study has laid out the steps that connect the neuromuscular disorder spinal muscular atrophy (SMA) to the mutations in the gene SMN1 that cause the condition. The research may explain how the mutations affect motor neurons and points the way to a better understanding of SMA.

READ MORE

KRAS Inhibitor Sotorasib Achieves Durable Clinical Benefit in Early Trial

News

In a Phase I clinical trial for patients with advanced solid cancers marked by KRAS G12C mutations, the KRASG12C inhibitor sotorasib (AMG 510) resulted in manageable toxicities and durable clinical benefit.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE